Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sona NanotechSNANF 26 3-Year RORE % is -1.18 as of Apr. 2026. GuruFocus rates SNANF with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 1,291 Biotechnology companies, Sona Nanotech ranks worse than 77459.26% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Sona Nanotech's 3-Year RORE % for the quarter that ended in Apr. 2026 was -1.18%.
The industry rank for Sona Nanotech's 3-Year RORE % or its related term are showing as below:
SNANF's 3-Year RORE % is not ranked
in the Biotechnology industry.
Industry Median: -11.44
vs SNANF: -1.18
Sona Nanotech (OTCPK:SNANF) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Sona Nanotech 3-Year RORE % Related Terms
Sona Nanotech 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Sona Nanotech's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sona Nanotech's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sona Nanotech 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sona Nanotech's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Sona Nanotech's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Apr. 2026 and 3-year before.
Sona Nanotech (SNANF) has a 3-Year RORE % of -1.18 as of Apr. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Sona Nanotech and its competitors. According to the industry distribution chart, Sona Nanotech ranks #999999 out of 1291 companies in the Biotechnology industry.
Is Sona Nanotech's 3-Year RORE % too high?
Sona Nanotech's current 3-Year RORE % is -1.18. Based on the distribution chart, Sona Nanotech ranks #999999 out of 1291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sona Nanotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Sona Nanotech's 3-Year RORE % compare to TMO and DHR?
According to the Biotechnology industry distribution chart, Sona Nanotech ranks #999999 out of 1291 companies for 3-Year RORE %. This places Sona Nanotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Sona Nanotech and its competitors. Sona Nanotech's current 3-Year RORE % is -1.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sona Nanotech stock overvalued right now?
Sona Nanotech (SNANF) has a current 3-Year RORE % of -1.18. The current 3-Year RORE % is -1.18. Sona Nanotech's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Sona Nanotech (SNANF), the current 3-Year RORE % is -1.18 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sona Nanotech Inc is involved in the nanotechnology life sciences industry. It has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles and is engaged in the research and development of its proprietary technology for use in biomedical applications and multiplex diagnostic testing platforms. The company is using its gold nano rods manufacturing technology to develop new products and methods for cancer treatment, including a Targeted Hyperthermia Therapy (THT). Additionally, it has filed patent applications in the U.S. regarding a gold nanorod conjugation concept for targeted drug delivery, combination therapies for treating cancer, and for an endoscope with an optical fibre and thermal sensor for photothermal therapy.
26GF Score
Get the complete analysis for SNANF
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNANF has been successfully added to your 
